Vaxcyte Inc (PCVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaxcyte Inc (PCVX) has a cash flow conversion efficiency ratio of -0.094x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-280.62 Million) by net assets ($3.00 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vaxcyte Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Vaxcyte Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Vaxcyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vaxcyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxcyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NIBE INDUSTR. UNSP.ADR/1
F:NJB0
|
0.065x |
|
AptarGroup Inc
NYSE:ATR
|
0.044x |
|
Ternium S.A
F:T5Z
|
0.013x |
|
Yapi ve Kredi Bankasi AS
IS:YKBNK
|
-0.472x |
|
Korea Investment Holdings Co
KO:071050
|
0.100x |
|
Planet Labs PBC
NYSE:PL
|
0.082x |
|
HUAYU Automotive Systems Co Ltd
SHG:600741
|
0.053x |
|
Hangzhou Lion Electronics Co Ltd
SHG:605358
|
0.029x |
Annual Cash Flow Conversion Efficiency for Vaxcyte Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Vaxcyte Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vaxcyte Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.69 Billion | $-655.58 Million | -0.244x | -78.29% |
| 2024-12-31 | $3.31 Billion | $-452.63 Million | -0.137x | +42.77% |
| 2023-12-31 | $1.24 Billion | $-296.79 Million | -0.239x | -33.74% |
| 2022-12-31 | $953.61 Million | $-170.60 Million | -0.179x | +58.14% |
| 2021-12-31 | $284.02 Million | $-121.39 Million | -0.427x | -217.02% |
| 2020-12-31 | $345.84 Million | $-46.63 Million | -0.135x | -130.42% |
| 2019-12-31 | $-106.37 Million | $-47.15 Million | 0.443x | -16.02% |
| 2018-12-31 | $-57.73 Million | $-30.47 Million | 0.528x | +109219.53% |
| 2017-12-31 | $30.94 Million | $-14.96K | 0.000x | -- |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more